Jazz Pharmaceuticals Reports Q4 Revenue Up 10.1% at $1.2 B, EPS $6.64; Shares Soar
Jazz Pharmaceuticals posted Q4 2025 revenue of $1.2 billion, a 10.1% year-over-year increase, and delivered adjusted EPS of $6.64, topping analyst projections. Operating margin expanded to 21.2% from 17.5% year-ago, driving a 13.5% intraday share surge and a further 5% rise in after-hours trading despite below-consensus full-year guidance.
1. Earnings and Revenue Results
Jazz Pharmaceuticals posted Q4 2025 revenue of $1.2 billion, up 10.1% year-over-year, and delivered adjusted EPS of $6.64 per share, both surpassing analyst forecasts.
2. Operational Efficiency
The company expanded its operating margin to 21.2%, up from 17.5% a year earlier, reflecting improved cost controls and higher sales mix in neuroscience and oncology segments.
3. Share Price Movement
The strong quarterly performance drove a 13.5% intraday share surge, followed by an additional 5% gain in after-hours trading, marking one of Jazz’s largest moves in a year.
4. Full-Year Guidance
Despite robust Q4 results, Jazz Pharmaceuticals issued full-year revenue guidance below consensus estimates, prompting discussions on potential growth headwinds in upcoming quarters.